Alpha-1 Antitrypsin Deficiency, AATD

Intellia Obtains UK Clearance to Begin Gene...
CMN Clinical

Jul. 31, 2024

Intellia Therapeutics announced yesterday that the UK’s Medicine and Healthcare products Regulatory Agency has cleared its clinical trial application...

The Latest Updates From the Gene-Editing Clinical...
CMN Clinical

Jul. 17, 2024

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...

Alpha-1 Antitrypsin Deficiency, AATD

Alpha-1 Antitrypsin Deficiency, AATD, (NCT06622668)
Sponsors:
Intellia Therapeutics
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Alpha-1 Antitrypsin Deficiency, AATD, (NCT06405633)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Alpha 1-Antitrypsin Deficiency, AATD, (NCT06389877)
Sponsors:
Beam Therapeutics Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Alpha-1 Antitrypsin Deficiency, AATD, (NCT06186492)
Sponsors:
Wave Life Sciences Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine